Benzinga | Mar 31, 2021 07:37AM EDT

Maxim Group Initiates Coverage On Amryt Pharma with Buy Rating, Announces Price Target of $27

Maxim Group initiates coverage on Amryt Pharma (NASDAQ:AMYT) with a Buy rating and announces Price Target of $27.